Aurobindo Pharma Q1 net rises 25% to ₹1,032 cr; approves merger of three arms
The U.S. formulations revenue increase was primarily driven by volume gains and new launches, partially offset by no transient product sales; Europe formulations revenue driven by robust performance across all key market.
· 8/5/2026, 3:54:16 PM· 2 min read
The U.S. formulations revenue increase was primarily driven by volume gains and new launches, partially offset by no transient product sales; Europe formulations revenue driven by robust performance across all key market.
Read original story →Related stories
business
Google shakes up AI leadership as DeepMind chief Demis Hassabis shifts role
business
ONGC expects oil plus gas production of 39 MMTOE this fiscal, 40 MMTOE next year
business
India may charge gas users to fund planned $42 billion fuel reserves, sources say
business